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ABSTRACT 
Objective: To assess the cost-effectiveness of chemohormonal 
therapy in patients with metastatic hormone-sensitive and non-
metastatic high-risk prostate cancer. Methods: An analytical 
decision model was developed to determine the cost-effectiveness of 
chemohormonal therapy versus androgen deprivation therapy alone 
in patients with metastatic hormone-sensitive prostate cancer and 
patients with non-metastatic high-risk prostate cancer. The cost-
effectiveness in metastatic patients with a high-volume disease was 
assessed separately. The model used data from randomized clinical 
trials and drug acquisition costs in Brazil. In addition, the costs of 
post-progression therapies have been included in this model. The 
benefits to health are expressed as the quality-adjusted life-years, and 
the incremental cost-effectiveness ratios were calculated. Results: 
Chemohormonal therapy may be associated with improved quality-
adjusted life-years for all patient. The improvement was more than 
six times greater for patients with high-volume metastatic disease. In 
these patients, the incremental cost-effectiveness ratios were up to 
74% lower than the incremental cost-effectiveness ratios of patients 
with non-metastatic disease. Conclusion: Chemohormonal therapy 
has been more cost-effective in patients with high-volume metastatic 
disease.
Keywords: Economics, pharmaceutical; Prostatic neoplasms/drug 
therapy; Cost control; Public health
RESUMO
Objetivo: Avaliar a relação custo-efetividade da adição de quimioterapia 
hormonal em pacientes com câncer de próstata metastático sensível 
a hormônio ou localizado de alto risco. Métodos: Um modelo de 
decisão analítico foi desenvolvido para determinar o custo-efetividade 
da adição de quimioterapia versus a monoterapia de privação de 
andrógeno para pacientes com câncer de próstata metastático 
hormônio-sensível e pacientes de alto risco com câncer de próstata 
não metastático. O custo-efetividade em pacientes metastáticos com 
um alto volume da doença foi verificado isoladamente. Os dados do 
modelo foram obtidos de ensaios clínicos randomizados utilizando 
custos de aquisição de medicamentos no Brasil. Os custos de terapias 
pós-progressão também foram incluídos no modelo. Os efeitos 
foram expressos em anos de vida ajustados por qualidade, e foram 
calculadas as razões de custo-efetividade incremental. Resultados: 
A adição de quimioterapia levou a um ganho de anos de vida ajustados 
por qualidade para todos os doentes. Este incremento foi seis vezes 
maior para os pacientes com doença metastática de alto volume. 
Nestes pacientes, as taxas do custo incremental por anos de vida 
ajustados por qualidade foram até 74% mais baixos do que o aumento 
das taxas dos pacientes com doença não metastática. Conclusão: 
A adição de quimioterapia foi mais custo-efetiva para pacientes com 
doença metastática de alto volume.
Descritores: Farmacoeconomia; Neoplasias da próstata/tratamento 
farmacológico; Controle de custos; Saúde pública
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INTRODUCTION
Prostate cancer is the second most common neoplasm 
in men worldwide with an estimated 1,100,000 new 
cases and 307,000 deaths reported in 2012.(1) In Brazil, 
between 2016 and 2017, the Instituto Nacional de 
Cancer José Alencar Gomes da Silva (INCA) estimates 
that prostate cancer will be the most common neoplasm 
among men, excluding non-melanoma skin cancers.(2)
U.S. data indicate that of all prostate cancer cases, 
80% are confined to the prostate gland, 12% are locally 
advanced and invaded regional lymph nodes, and 4% 
are distant metastases; approximately 4% of the cases 
have an unknown stage.(3) Although the lack of data 
in Brazil, it is hypothesized that there will be a greater 
proportion of metastatic disease reported at diagnosis 
due to socioeconomic reasons.(4)
The main treatment for metastatic disease has been 
androgen deprivation therapy (ADT) since mid-1966, 
when Charles B. Huggins was awarded with the Nobel 
Prize. He showed that androgen deprivation was an 
effective treatment in patients with locally advanced 
or metastatic prostate cancer, with a 15% decrease in 
the cancer-specific mortality rate.(5) However, there was 
no change in the overall survival (OS) of patients with 
localized disease.(5)
Recent studies have reviewed this treatment 
paradigm and have compared ADT alone versus 
ADT in combination with chemotherapy for patients 
with localized, advanced, or metastatic disease. The 
GETUG-AFU 15 study (Androgen-deprivation therapy 
alone or with docetaxel in non-castrate metastatic prostate 
cancer) did not show any improvement in OS following 
treatment with ADT plus docetaxel versus ADT alone; 
however, an objective response rate of 28% was achieved 
in patients who were treated with a combination of 
ADT and docetaxel.(6) The median progression free 
survival (PFS) for the ADT plus docetaxel group 
increased to 23.4 months from 18.5 months for the 
ADT group (hazard ratio - HR: 0.75, 95% of confidence 
interval - 95%CI: 0.59-0.94; p=0.015).(6)
In addition, the Systemic Therapy in Advancing or 
Metastatic Prostate Cancer: Evaluation of Drug Efficacy 
(STAMPEDE) and GETUG-AFU 12 studies have 
assessed chemotherapy plus ADT for non-metastatic 
patients with a high-risk of localized disease (e.g. elevated 
prostate specific antigen − PSA at diagnosis and high-
grade tumors). In the STAMPEDE study, 24% of the 
patients did not present with metastatic disease and the 
results of the study pointed to a benefit in terms of OS 
and PFS in favor of the combined treatment.(7) In the 
GETUG-AFU 12 study, which only included patients 
with non-metastatic disease, there was an increase in the 
recurrence free survival (RFS) in patients that received 
the combination treatment of chemotherapy plus ADT 
compared to patients that were treated with ADT alone 
(HR: 0.71; p=0.017).(8)
Pharmacoeconomics evaluates the costs and benefits 
of drug therapy under the following aspects: the cost 
of this treatment to the health system, how much it 
improves disease prognoses, the demand and supply 
of the treatment for a given disease, and the budget.(9) 
The main objective of pharmacoeconomics is to equate 
the increasing financial demand of new treatments with 
sustainability, so that the treatment for a specific subset 
of the population is available for everyone who will 
benefit the most.(9) There are two important concepts 
to consider: the quality-adjusted life-year (QALY) and 
incremental cost-effectiveness ratio (ICER).(10)
Quality-adjusted life-year measures both the number 
of years gained by taking a treatment and the quality 
of life during the treatment period. This is measured in 
terms of the patient’s ability to carry out daily activities. 
This is the life-years provided by the treatment adjusted 
to the quality of life score (also known as utility, on a 
scale of zero, dead, to 1, full capacity).(10)
Incremental cost-effectiveness ratio evaluates the 
cost-effectiveness of the treatment intervention, i.e., the 
cost for each QALY gained by the treatment. The value 
is the ratio between the difference in treatment costs 
and the QALY gained.(10)
OBJECTIVE
To evaluate the cost-effectiveness of adding chemotherapy 
to androgen deprivation therapy in three distinct 
subgroups of patients with prostate cancer: patients with 
metastatic disease, patients with extensive metastatic 
disease and patients with high-risk non-metastatic 
disease.
METHODS
We developed an analytical model to determine the 
cost-effectiveness of adding chemotherapy to ADT 
versus ADT alone for the initial treatment of prostate 
cancer. In our model, we compared early chemotherapy 
plus ADT or ADT alone. The model was developed in 
the Microsoft Excel Professional Plus 2013.
The type of treatment after progression and death 
(Figure 1) were also included. The same model was 
applied to patients with hormone-sensitive metastatic 
disease and high-risk non-metastatic disease. Subsequently, 
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analyses were performed considering only the metastatic 
patients with a high-volume of disease according to the 
definitions of the CHAARTED study (ChemoHormonal 
therapy versus androgen ablation randomized trial 
for extensive disease in prostate câncer): presence of 
visceral metastasis and/or four or more lesions in the 
bone with at least one lesion affecting a bone outside of 
the vertebrae or pelvis.(11)
To calculate the QALY of each treatment, the 
different health states present in the model received 
a utility score based on the literature.(12) The utility 
score for chemotherapy was obtained from quality of 
life analyzes previously published.(8,11) Utility values 
were reduced according to the adverse events caused 
by each first-line treatment using the disutility scores 
available in the literature.(13-15)
The costs for each treatment and the costs of the 
post-progression therapies were considered. These 
costs were based on the Brazilian discount price index 
accessed in June 2016.(16) All costs were converted 
to US dollars based on an exchange rate of R$ 3,25 
to US$ 1.00. The costs of adverse events were not 
considered in the Brazilian model because there has 
not been enough data published in the local literature 
to extrapolate the costs from other countries (such as 
the United States or the United Kingdom), which may 
not accurately represent the reality in Brazil. All costs 
included in the analysis are summarized in the table 1.
each study was adequate to demonstrate the difference 
in outcomes between each type of treatment (8.8 years 
in the GETUG-AFU 12 study and 28.9 months in the 
CHAARTED study).(8,11) The effects were expressed in 
QALY and ICER.
After analyzing the clinical scenario of each group 
of patients a probabilistic sensitivity analysis was 
performed, taking into account the CI of RFS, PFS 
and OS. In addition, scenarios with 100% increase or 
50% discount on the cost of docetaxel cost and QALY 
gain were considered. These analyses were performed 
to confirm the robustness of the data and facilitate the 
comparison of the results between the different patient 
subgroups. The probabilistic sensitivity analysis results 
are presented in a Tornado diagram. 
RESULTS
High-risk non-metastatic disease
In the analysis of patients with high-risk non-metastatic 
disease, the addition of docetaxel to ADT promoted a 
gain of 0.12 QALY. As a result, the incremental cost 
of this therapy was US$ 25,929.62 per QALY. In the 
probabilistic sensitivity analysis, 53% of the scenarios 
evaluated were cost-effective based on the three-fold 
gross domestic product (GDP) per capita (US$ 33,000.00) 
per QALY. In 33% of the scenarios evaluated ADT 
alone was cost-effective (Figure 2).
ADT: androgen deprivation therapy.
Figure 1. Type of treatment after progression and death
Table 1. Costs summary
Costs Docetaxel + ADT ($) ADT alone ($)
Docetaxel  4,733.90 0
ADT  5,441.74 3,886.95
Post progression  9,618.64 9,863.14
Adverse events NA NA
Supportive care  NA NA
Total  19,794.28 13,750.09
NA: not assessed; ADT: androgen deprivation therapy.
Doc: docetaxel; M0: non-metastatic; M1: all metastatic; QALY quality-adjusted life-year; PFS: progression-free survival; 
OS: overall survival; Hi: metastatic with high volume of disease; ADT: androgen deprivation therapy; ICER: incremental 
cost-effectiveness ratio; CI: confidence interval.
Figure 2: Tornado diagram for docetaxel plus androgen deprivation therapy 
versus androgen deprivation therapy alone
Metastatic disease
In the metastatic disease analysis, there was an increase 
of 0.53 QALY with the addition of docetaxel to ADT. 
The incremental cost per patient was R$ 11.228.55 per 
Data regarding PFS, or RFS in the case of non-
metastatic patients, and OS were extracted from 
randomized clinical trials.(8,11) A lifetime mortality 
estimate was not made since the follow-up time for 
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QALY. Almost all of the scenarios evaluated in the 
probabilistic sensitivity analysis were considered cost-
effective (80% of the cases). In the remaining (20%) 
scenarios, ADT alone was cost effective (Figure 2).
High-volume metastatic disease
Considering only patients with a high-volume of 
metastatic disease, there was an increase of 0.70 QALY 
with the addition of docetaxel to ADT. The incremental 
cost in this subpopulation was US$ 8,416.93 per QALY. 
The majority of scenarios evaluated in the PSA were 
within the cost-effectiveness threshold (73%). In this 
subgroup, ADT alone was not considered to be cost-
effective (Figure 2).
Figure 3 presents all of the scenarios considered 
in the probabilistic sensitivity analysis including all of 
the patient subgroups evaluated in the model. This is a 
scatter plot in which each point represents a probabilistic 
analysis. The subgroups can be viewed together in 
different colors. The diagonal lines represent the cost-
effectiveness thresholds according to the definitions 
of the World Health Organization:(17) treatments that 
cost less than the value of one GDP per capita for each 
QALY gained are very cost-effective and treatments 
that cost up to three times the value of the GDP per 
capita for each QALY gained are cost-effective.
with high-volume or more aggressive metastatic disease 
as a result of the differences between the GETUG-AFU 15 
and CHAARTED studies.(6,18) The first study included 
about 30% of patients with high-volume disease and 
did not find a benefit, while the second study included 
70% of individuals with high-volume disease and found 
a statistically significant benefit.(6,11)
The aging population in Brazil may lead to an 
increase in the number of individuals with cancer.(19) 
Furthermore, the development of potentially expensive 
new technologies may lead to a significant increase in 
cancer treatment costs.(20) In Brazil, the expenses in 
cancer drug acquisition has increased almost three times 
in the past ten years.(21) Approximately U$ 2.5 billion 
are spent each year on cancer drugs.(21) Therefore, it is 
fundamental to evaluate the cost-effectiveness of the 
treatments.
Although the relevance of cost-effectiveness analyses 
are increasing, there is still great difficulty in defining an 
accepted ICER threshold.(20) In an attempt to facilitate 
the interpretation of these data, the World Health 
Organization suggests that for a treatment to be cost-
effective it must cost up to three times the value of GDP 
per capita per QALY gained, and for a treatment to be 
very cost-effective it must cost less than the GDP per 
capita.(17) In the US the cost-effectiveness threshold is 
US$ 50,000 per QALY gained. This value is based on the 
costs required for hemodialysis treatment for patients 
with chronic renal failure. However, recent studies 
suggest this figure should be increased to US$ 100,000 
or US$ 150,000.(22) In the United Kingdom, the most 
commonly used threshold is £ 30,000.00 per QALY.
Considering these cost-effectiveness thresholds, 
we consider that the findings in this study are robust 
since they fall within the cost-effectiveness thresholds 
in the majority of the probabilistic sensitivity analysis 
performed. The most cost-effective treatment group 
was patients with high volume metastatic disease (up 
to six times more cost-effective compared to patients 
with non-metastatic neoplasms).
In the other hand, a Chinese study assessed the 
same question in China. The addition of docetaxel 
was not cost-effective for all patients with metastatic 
disease, although this treatment may be cost-effective 
for a minority of sensitivity analysis among patients 
with disease of high-volume. The incremental QALY 
found by the Chinese authors and by our group are 
quite similar.(23) This endorses the replicability and 
robustness of our findings. Moreover, our study was the 
only that assessed the cost-effectiveness of the addition 
of docetaxel to ADT for non-metastatic disease.
M0: non-metastatic; M1: all metastatic; QALY quality-adjusted life-year.
Figure 3. Cost-effectiveness of docetaxel plus androgen deprivation therapy for 
prostate cancer
DISCUSSION
The addition of chemotherapy to androgen deprivation 
therapy (ADT) represented a paradigm shift when initially 
used for the treatment of prostate cancer.(6-8,11,18) However, 
there was a more pronounced practice change for patients 
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Although the thresholds proposed by World Health 
Organization facilitate the interpretation of cost-
effectiveness studies and the definition of the 
implementation of new technologies, these values 
consider only economic aspects of the population. 
Epidemiological, cultural, psychological, and spiritual 
aspects are not taken into account in this evaluation. 
For example, new treatment for a rare disease with 
limited therapeutic options may accept a higher cost-
effectiveness threshold than a new treatment for a 
prevalent disease with good therapeutic options.
In addition, the discussion about the monetary value 
that should be invested in an individual’s life is very 
complex in Brazilian society. Furthermore, it is very 
difficult to standardize cost-effectiveness thresholds for 
individuals in different social strata.
There are fundamental questions regarding the 
interpretation of these findings that have not been 
fully addressed. One of the major limitations of this 
study was that the estimate of the quality of life based 
on data from the literature may be different from the 
Brazilian values and lead to possible changes in the 
findings. Since there are no Brazilian data to be used, 
it is extremely important to develop other quality of life 
studies in Brazil.
In our study, we included clinical data from 
randomized studies within populations outside of 
Brazil, which may differ from studies conducted in a 
Brazilian population. Therefore, the need for clinical 
studies in Brazil is required to confirm that data from 
international clinical studies are relevant.
CONCLUSION
The addition of chemotherapy to the hormone treatment 
of prostate cancer is a cost-effective measure for 
patients with extensive (high-volume) metastatic disease. 
However, studies regarding the clinical effectiveness 
and quality of life are necessary to confirm these findings 
in Brazil.
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